Investor Alert

Market Pulse Archives

Aug. 17, 2022, 2:59 p.m. EDT

Bluebird announces FDA approval of gene therapy for rare blood disease

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    bluebird bio Inc. (BLUE)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Buebird Bio Inc. /zigman2/quotes/207450173/composite BLUE +11.05% jumped 12.1% in trading on Wednesday after the Food and Drug Administration approved the company's gene therapy as a treatment for beta‑thalassemia in some adult and pediatric patients. Beta-thalassemia is a rare, genetic blood disease, and the patients who qualify for the treatment require regular red blood cell transfusions. The one-time wholesale acquisition price for Zynteglo is $2.8 million. Bluebird also announced an outcomes-based agreement in which the company will reimburse commercial and government payers up to 80% of the total cost if a patient fails to stay transfusion-free for two years. Bluebird's stock has tumbled 25.9% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -1.51% is down 9.6%. fdsup://factset/Doc%20Viewer%20Single?_expand=oE8Pv7&float_window=true EST (833-888-6378) for more information, and additional details will be available at mybluebirdsupport.com in the coming days. ZYNTEGLO was reviewed under Priority Review, and the Company received a Priority Review voucher upon approval. ZYNTEGLO was previously granted Orphan Drug designation and Breakthrough Therapy designation.

US : U.S.: Nasdaq
$ 6.33
+0.63 +11.05%
Volume: 10.34M
Sept. 30, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$488.18 million
Rev. per Employee
-54.85 -1.51%
Volume: 2.22B
Sept. 30, 2022 5:55p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.